CN1713900A - 去甲肾上腺素再摄取抑制剂在治疗认知障碍中的应用 - Google Patents

去甲肾上腺素再摄取抑制剂在治疗认知障碍中的应用 Download PDF

Info

Publication number
CN1713900A
CN1713900A CNA028247264A CN02824726A CN1713900A CN 1713900 A CN1713900 A CN 1713900A CN A028247264 A CNA028247264 A CN A028247264A CN 02824726 A CN02824726 A CN 02824726A CN 1713900 A CN1713900 A CN 1713900A
Authority
CN
China
Prior art keywords
treatment
application
tomoxetine
cognitive disorder
chemical compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028247264A
Other languages
English (en)
Chinese (zh)
Inventor
F·P·拜马斯特
D·R·格莱尔特
D·L·麦金兹
C·R·杨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN1713900A publication Critical patent/CN1713900A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CNA028247264A 2001-12-11 2002-11-27 去甲肾上腺素再摄取抑制剂在治疗认知障碍中的应用 Pending CN1713900A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33917401P 2001-12-11 2001-12-11
US60/339,174 2001-12-11

Publications (1)

Publication Number Publication Date
CN1713900A true CN1713900A (zh) 2005-12-28

Family

ID=23327833

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028247264A Pending CN1713900A (zh) 2001-12-11 2002-11-27 去甲肾上腺素再摄取抑制剂在治疗认知障碍中的应用

Country Status (26)

Country Link
US (1) US20050009925A1 (https=)
EP (1) EP1458368B1 (https=)
JP (1) JP2005517647A (https=)
KR (1) KR20040066895A (https=)
CN (1) CN1713900A (https=)
AU (1) AU2002352625A1 (https=)
BR (1) BR0213581A (https=)
CA (1) CA2467802A1 (https=)
CO (1) CO5590907A2 (https=)
CZ (1) CZ2004709A3 (https=)
DE (1) DE60223718T2 (https=)
EA (1) EA200400793A1 (https=)
EC (1) ECSP045145A (https=)
ES (1) ES2295435T3 (https=)
HR (1) HRPK20040528B3 (https=)
HU (1) HUP0402619A3 (https=)
IL (1) IL161989A0 (https=)
MX (1) MXPA04005716A (https=)
MY (1) MY136367A (https=)
NO (1) NO20042904L (https=)
NZ (1) NZ532065A (https=)
PL (1) PL369311A1 (https=)
SK (1) SK2442004A3 (https=)
TW (1) TW200300672A (https=)
WO (1) WO2003049724A1 (https=)
ZA (1) ZA200404274B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1530476A1 (en) * 2002-08-14 2005-05-18 Pharmacia & Upjohn Company LLC Use of reboxetine for the treatment of hot flashes
EP1708717B1 (en) * 2003-07-28 2011-10-05 Leslie Joe Dunaway Atomoxetine for treatment of allergic rhinitis and asthma
EP1660064A2 (en) * 2003-08-27 2006-05-31 Eli Lilly And Company Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors
EP1729754B1 (en) * 2003-12-12 2008-07-02 Eli Lilly And Company Selective norepinephrine reuptake inhibitors for the treatment of hot flashes
BRPI0510453A (pt) * 2004-04-30 2007-10-30 Warner Lambert Co composto substituìdos com morfolina para o tratamento de distúrbios do sistema nervoso central
US7439399B2 (en) * 2004-06-28 2008-10-21 Teva Pharmaceutical Fine Chemicals Processes for the preparation of atomoxetine hydrochloride
US8580776B2 (en) * 2007-07-10 2013-11-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating neurodegenerating diseases
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
US20100317730A1 (en) * 2009-06-12 2010-12-16 Shaya Elias K Treatment for menopausal and perimenopausal vasomotor symptons
WO2011014475A2 (en) * 2009-07-31 2011-02-03 National Taiwan University Treating negative symptoms of schizophrenia associated with defective neuregulin 1
JP6126531B2 (ja) * 2011-10-03 2017-05-10 国立研究開発法人国立長寿医療研究センター タウ凝集阻害剤
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
US9907799B2 (en) 2013-04-02 2018-03-06 The Doshisha Tau aggregation inhibitor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
US5281624A (en) * 1991-09-27 1994-01-25 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
US5658590A (en) * 1995-01-11 1997-08-19 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
US6465458B1 (en) * 1999-07-01 2002-10-15 Pharmacia & Upjohn Company Method of treating or preventing chronic pain with a highly selective norepinephrine reuptake inhibitor
AP2002002481A0 (en) * 1999-10-13 2002-06-30 Pfizer Prod Inc Biaryl ether derivatives useful as monoamine reuptake inhibitors.
AU2002243451A1 (en) * 2001-01-02 2002-07-16 Sention, Inc. Use of catecholamine reuptake inhibitors to enhance memory
JP2004517112A (ja) * 2001-01-02 2004-06-10 ファルマシア・アンド・アップジョン・カンパニー 新規薬物コンビネーション

Also Published As

Publication number Publication date
BR0213581A (pt) 2004-08-24
CA2467802A1 (en) 2003-06-19
DE60223718D1 (de) 2008-01-03
US20050009925A1 (en) 2005-01-13
ECSP045145A (es) 2004-07-23
KR20040066895A (ko) 2004-07-27
DE60223718T2 (de) 2008-10-30
ZA200404274B (en) 2005-09-13
HRPK20040528B3 (en) 2006-03-31
CZ2004709A3 (cs) 2004-10-13
AU2002352625A1 (en) 2003-06-23
EP1458368A1 (en) 2004-09-22
HUP0402619A2 (hu) 2005-03-29
TW200300672A (en) 2003-06-16
JP2005517647A (ja) 2005-06-16
SK2442004A3 (en) 2004-12-01
MXPA04005716A (es) 2004-12-06
CO5590907A2 (es) 2005-12-30
WO2003049724A1 (en) 2003-06-19
NO20042904L (no) 2004-09-07
EP1458368B1 (en) 2007-11-21
ES2295435T3 (es) 2008-04-16
EA200400793A1 (ru) 2004-10-28
NZ532065A (en) 2007-03-30
HRP20040528A2 (en) 2004-10-31
IL161989A0 (en) 2005-11-20
PL369311A1 (en) 2005-04-18
HUP0402619A3 (en) 2008-04-28
MY136367A (en) 2008-09-30

Similar Documents

Publication Publication Date Title
DE60200492T2 (de) Kombination eines Inhibitoren der Serotoninwiederaufnahme und eines atypischen Antipsychotikums zur Behandlung von Depression, Zwangsneurosen und Psychosen
US10004731B2 (en) Flibanserin for the treatment of urinary incontinence and related diseases
RU2336879C2 (ru) Применение n-десметилклозапина для лечения нейропсихиатрических заболеваний у людей
CN1713900A (zh) 去甲肾上腺素再摄取抑制剂在治疗认知障碍中的应用
US9808455B2 (en) Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
US9610287B2 (en) Method of administration of 4-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and the salts thereof in the treatment of schizophrenia
CA2989319C (en) Pharmaceutical compositions for anesthesiological applications
US20080107756A1 (en) Lithium combinations, and uses related thereto
CN1311681A (zh) 顽固性抑郁治疗的联合疗法
US6960577B2 (en) Combination therapy for treatment of refractory depression
KR20020083138A (ko) 우울증의 치료 또는 인지 기능 감퇴의 예방 방법 및 키트
CN1252722A (zh) 脱羰乙氧氯雷他定在治疗尿失禁、晕动病和眩晕药剂的制备中的应用
JP2008525414A (ja) 精神病性障害を治療するためのサブコメリンと神経遮断薬との組み合わせ
US20240415848A1 (en) Pharmaceutical compositions and methods for anesthesiological applications
KR20090069340A (ko) 이명 및 청력 손실의 치료를 위한 ｎｋ-1 수용체 길항제 및 ｓｓｒｉ를 포함하는 조성물
US20110065749A1 (en) Method and pharmaceutical composition for treatment of mental disorders
HK40113104A (en) Pharmaceutical compositions for anesthesiological applications
Post-MI IV. MEDICAL CAUSES OF DEPRESSION
CN1802168A (zh) 用于神经元再生和功能恢复的σ配体
HK1253720B (en) Pharmaceutical compositions for anesthesiological applications comprising benzodiazepine and ketamine
HK1063744A (en) Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders
HK1118712A (en) Multimediator dopamine transport inhibitors, and uses related thereto

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20051228